Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005856 · ClinicalTrials.gov registry record · Phase 1
Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT00005856: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00005856 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005856, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
This phase I/II trial is studying the side effects and best dose of oxaliplatin in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing
Interventions
- DRUG oxaliplatin
- OTHER pharmacological study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2000-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005856
The ClinicalTrials.gov registry entry for NCT00005856 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which oxaliplatin is the first listed.
NCT00005856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005856 about?
NCT00005856 is a clinical study titled "Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". This phase I/II trial is studying the side effects and best dose of oxaliplatin in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping the...
What is the current status of trial NCT00005856?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2000-12.
What interventions are being tested in trial NCT00005856?
The interventions under investigation include: oxaliplatin (DRUG), pharmacological study (OTHER).
Who is sponsoring clinical trial NCT00005856?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.